Clinical trials: Stage IV Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously treated lung cancer that has spread in the body.
- Trial name
- NCT00697060
- Testing
- Imexon + docetaxel
- Where
- 3 sites in United States
- Sponsor
- AmpliMed Corporation
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04466917
- Testing
- ABP 215, Bevacizumab, Paclitaxel
- Sponsor
- Amgen
Non-small Cell Lung Cancer
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in…
- Trial name
- NCT05775289
- Testing
- Tobemstomig, Pembrolizumab, Paclitaxel
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
- Trial name
- Morpheus Lung (NCT03337698)
- Testing
- Atezolizumab, Cobimetinib, RO6958688
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or…
- Trial name
- NCT07680790
- Testing
- Iza-bren, Osimertinib, Pemetrexed
- Where
- 204 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-small Cell Lung Cancer (NSCLC)
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
The primary scientific question of interest is whether the addition of ociperlimab to platinum-based chemotherapy and tislelizumab improve progression-free survival (PFS) or overall survival (OS) compared to pembrolizumab and…
- Trial name
- AdvanTIG-306 (NCT05791097)
- Testing
- Ociperlimab, Tislelizumab, Pembrolizumab
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07467863)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of momelotinib (MMB) and erlotinib, as well as define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with erlotinib in adults…
- Trial name
- NCT02206763
- Testing
- Momelotinib (MMB), Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Non-Small Cell Lung Cancer
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT06883630
- Testing
- RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- RemeGen Co., Ltd.
NSCLC
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
This is a multicenter, open-label, randomized phase 1 study of escalating doses of Tarceva in patients with advanced NSCLC who currently smoke. Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.
- Trial name
- NCT00294736
- Testing
- Tarceva
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 57 people
- Sponsor
- OSI Pharmaceuticals
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Carcinoma, Non-Small-Cell Lung
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
- Trial name
- REVEAL (NCT03761901)
- Testing
- 1L treatment, 2L Treatment, 3L treatment
- Where
- 15 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- NCT03829332
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 162 sites in United States, Australia and 17 more
- Volunteers
- 623 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV…
- Trial name
- NCT01519804
- Testing
- cisplatin/carboplatin, onartuzumab, paclitaxel
- Where
- 69 sites in United States, Argentina and 7 more
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Malignant Pleural Effusions, NSCLC Stage IV
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
- Trial name
- NCT05543330
- Testing
- M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
NSCLC, EGFR Activating Mutation
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
- Trial name
- NCT05382728
- Testing
- TY-9591, Osimertinib
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- TYK Medicines, Inc
Non-Small Cell Lung Cancer
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet…
- Trial name
- CheckMate 078 (NCT02613507)
- Testing
- Nivolumab, Docetaxel
- Where
- 33 sites in China, Hong Kong and 2 more
- Volunteers
- 504 people
- Sponsor
- Bristol-Myers Squibb